EGFR/ErbB-2 inhibitors (GlaxoSmithKline)

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameEGFR/ErbB-2 inhibitors (GlaxoSmithKline)
Drug Alias Namequinolines & quinazolines (GlaxoSmithKline)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsPsoriasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxo Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcGlaxo Group Ltd
Active IndicationsN/A
Inactive IndicationsPsoriasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A